| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Chrysosplenetin targets multiple pathways. It is a metabolic inhibitor of artemisinin. The compound has strong activity against Enterovirus 71 (EV71) in vitro with low cytotoxicity. It is active against P. falciparum with an IC50 of 23 µM. Chrysosplenetin is a polymethoxylated flavonoid with potential as an adjuvant in malaria treatment. Its mechanism involves modulation of metabolic and antiviral pathways.
|
|---|---|
| ln Vitro |
In vitro, Chrysosplenetin is a polymethoxylated flavonoid from Artemisia annua. It is active against P. falciparum with an IC50 of 23 µM. The compound has strong activity against Enterovirus 71 (EV71) with low cytotoxicity. It is a metabolic inhibitor of artemisinin. Chrysosplenetin has diverse biological activities. Its anti-malarial and antiviral activities have been characterized in various cell-based assays.
|
| ln Vivo |
In vivo, Chrysosplenetin has been studied as an adjuvant in malaria treatment. As a metabolic inhibitor of artemisinin, it may enhance the efficacy of artemisinin-based therapies. The compound is a polymethoxylated flavonoid from Artemisia annua and other Chinese herbs. Further in vivo studies are needed to fully characterize its therapeutic potential for malaria and viral infections.
|
| Enzyme Assay |
In vitro enzyme assays for Chrysosplenetin involve measuring its anti-malarial and antiviral activities. Anti-malarial activity is assessed by measuring inhibition of P. falciparum growth and determining IC50 values (23 µM). Antiviral activity against EV71 is assessed by measuring viral replication inhibition. Artemisinin metabolism inhibition is assessed by measuring artemisinin metabolism in the presence of the compound. Assays are performed in appropriate buffer systems with positive controls such as known anti-malarial agents.
|
| Cell Assay |
In vitro cell-based assays for Chrysosplenetin are conducted in P. falciparum cultures, virus-infected cells, and other relevant cell types. P. falciparum is cultured in appropriate media and treated with the compound at varying concentrations. Parasite growth is monitored and IC50 values are determined. For antiviral studies, EV71-infected cells are treated with the compound and viral replication is measured. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Chrysosplenetin in vivo studies are conducted in animal models of malaria and viral infections. Animals are infected with P. falciparum or EV71 and treated with Chrysosplenetin via oral administration or injection. Parasitemia or viral load is monitored. For adjuvant studies, the compound is combined with artemisinin to assess enhanced efficacy. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Chrysosplenetin (MW 374.34-374.4 g/mol, C19H18O8) is a polymethoxylated flavonoid. It is also known as 3,6,7,3'-Tetramethylquercetagetin. The compound has a purity of 98%. It is a metabolic inhibitor of artemisinin and has anti-malarial and antiviral activities. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Chrysosplenetin is generally well-tolerated in preclinical studies. The compound is a natural flavonoid with established safety profiles. Its anti-malarial and antiviral activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Chrysosplenetin is a tetramethoxyflavonoid, a 3,6,7,3'-tetramethyl ether derivative of quercetin. It possesses antiviral activity and is also a plant metabolite. It is a tetramethoxyflavonoid and a dihydroxyflavonoid, functionally related to quercetin. Chrysosplenetin has been reported to be found in Stylidocleome brachycarpa, Thulinella chrysantha, and other organisms with relevant data.
Chrysosplenetin is a polymethoxylated flavonoid from Artemisia annua and other Chinese herbs that is a metabolic inhibitor of artemisinin. It is active against P. falciparum in vitro (IC50 = 23 µM) and has strong activity against EV71 with low cytotoxicity. The compound has potential as an adjuvant in malaria treatment. Its molecular formula is C19H18O8 with a molecular weight of 374.34-374.4 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C19H18O8
|
|---|---|
| Molecular Weight |
374.3414
|
| Exact Mass |
374.1
|
| CAS # |
603-56-5
|
| Related CAS # |
603-56-5;
|
| PubChem CID |
5281608
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
615.8±55.0 °C at 760 mmHg
|
| Flash Point |
222.7±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
2.26
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
576
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NBVTYGIYKCPHQN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O8/c1-23-11-7-9(5-6-10(11)20)17-19(26-4)16(22)14-12(27-17)8-13(24-2)18(25-3)15(14)21/h5-8,20-21H,1-4H3
|
| Chemical Name |
5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,6,7-trimethoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~267.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6714 mL | 13.3568 mL | 26.7137 mL | |
| 5 mM | 0.5343 mL | 2.6714 mL | 5.3427 mL | |
| 10 mM | 0.2671 mL | 1.3357 mL | 2.6714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
